Research programme: antibacterials - BioWest

Drug Profile

Research programme: antibacterials - BioWest

Alternative Names: MBI 2046; MBI 2401; MBI-1396; MX 2401

Latest Information Update: 27 Jun 2012

Price : $50

At a glance

  • Originator Ardea Biosciences; BioSource Pharm
  • Developer Carrus Capital Corporation
  • Class Antibacterials; Lipoproteins; Peptides
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Gram-positive infections

Most Recent Events

  • 19 Aug 2011 BioWest Therapeutics is now called Carrus Capital Corporation
  • 15 Sep 2009 Pharmacodynamics data from a preclinical trial in Gram-positive infections presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009)
  • 15 Sep 2009 Antimicrobial data from preclinical trials of MX 2401 in Gram-positive infections presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009) ,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top